Generic Arimidex is used for treating breast cancer in women who have been through menopause, including women with disease progression after tamoxifen therapy. More info »
Well, I must apologize - I thought surely you were scamming me. But, all of
a sudden, my mailbox overflows. I received one order on Thursday, 8 June,
and then another on Saturday, 10 June. Almost 1 month from our first
effort, but the postal service must be the culprits. With this double
supply, you are now going to have to send me a couple of women, so the meds
don't go to waste. How can we make this right? What would you like me to
do? Thanks. I hope only good karma comes to you.
- Curt
Our NanoNews Digest SponsorsNanotechnology News (press release)The ABCSG8 study, initiated in 1996, demonstrated that compared to treatment with tamoxifen alone, sequential adjuvant treatment with tamoxifen followed by anastrozole in postmenopausal women with hormone receptor-positive early-stage breast cancer .
Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - MarketWatch (press release)
Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality ReductionMarketWatch (press release)Drugs covered include: Abiraterone acetate (Zytiga), Afatinib (Tomtovok), Afimoxifene (TamoGel), Albumin-bound paclitaxel (Abraxane), Anastrozole (Arimidex), Apatinib, Bevacizumab (Avastin), Bosutinib, Capecitabine (Xeloda), Cediranib, .
Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds ... - Linex Legal (press release) (registration)
Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds .
An object clause is not necessarily determinative of the promise of the patent - Lexology (registration)
An object clause is not necessarily determinative of the promise of the patentLexology (registration)Analysis – The `420 Patent relates to (substituted-aralkyl) – heterocyclic compounds, including anastrozole, and in particular, to such compounds which are useful as inhibitors of the enzyme aromatase.